ImmuCell Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmuCell in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ImmuCell stock.
View analyst ratings for ImmuCell or view top-rated stocks.

Wall Street analysts have given ImmuCell a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ImmuCell wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ImmuCell saw a increase in short interest in May. As of May 28th, there was short interest totaling 14,600 shares, an increase of 31.5% from the May 13th total of 11,100 shares. Based on an average daily trading volume, of 14,200 shares, the short-interest ratio is presently 1.0 days. Approximately 0.3% of the company's stock are short sold.
View ImmuCell's Short Interest.

ImmuCell is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for ImmuCell.

ImmuCell Co. (NASDAQ:ICCC) released its quarterly earnings results on Thursday, May, 13th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.05 by $0.11. The biotechnology company earned $4.11 million during the quarter. ImmuCell had a negative trailing twelve-month return on equity of 4.77% and a negative net margin of 9.22%.
View ImmuCell's earnings history.

ImmuCell's stock was trading at $4.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ICCC shares have increased by 126.0% and is now trading at $9.72.
View which stocks have been most impacted by COVID-19.

ImmuCell issued an update on its first quarter 2021 earnings guidance on Tuesday, May, 4th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $4.10 million-$4.10 million, compared to the consensus revenue estimate of $5.40 million.

1 brokerages have issued twelve-month target prices for ImmuCell's stock. Their forecasts range from $14.00 to $14.00. On average, they expect ImmuCell's share price to reach $14.00 in the next year. This suggests a possible upside of 44.0% from the stock's current price.
View analysts' price targets for ImmuCell or view top-rated stocks among Wall Street analysts.

Some companies that are related to ImmuCell include MyMD Pharmaceuticals (MYMD), Lucira Health (LHDX), VolitionRx (VNRX), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Navidea Biopharmaceuticals (NAVB), ARCA biopharma (ABIO), Biomerica (BMRA), Achieve Life Sciences (ACHV), Global WholeHealth Partners (GWHP), StageZero Life Sciences (GNWSF), StageZero Life Sciences (GNWSD), FluoroPharma Medical (FPMI), BG Medicine (BGMD) and Response Genetics (RGDXQ).
View all of ICCC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Biocept (BIOC), Amarin (AMRN), CorMedix (CRMD), CRISPR Therapeutics (CRSP), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Pfizer (PFE).

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

ImmuCell's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.42%), Morgan Stanley (0.71%), Wedge Capital Management L L P NC (0.28%), BlackRock Inc. (0.25%), Shufro Rose & Co. LLC (0.25%) and HighTower Advisors LLC (0.20%). Company insiders that own ImmuCell stock include David Cunningham and David Scott Tomsche.
View institutional ownership trends for ImmuCell.

ICCC stock was sold by a variety of institutional investors in the last quarter, including Shufro Rose & Co. LLC, Minerva Advisors LLC, Morgan Stanley, and HighTower Advisors LLC.
View insider buying and selling activity for ImmuCell or view top insider-selling stocks.

ICCC stock was acquired by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, O Shaughnessy Asset Management LLC, Flagship Harbor Advisors LLC, and BlackRock Inc.. Company insiders that have bought ImmuCell stock in the last two years include David Cunningham, and David Scott Tomsche.
View insider buying and selling activity for ImmuCell or or view top insider-buying stocks.

Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ICCC stock can currently be purchased for approximately $9.72.

ImmuCell has a market capitalization of $75.19 million and generates $15.34 million in revenue each year. The biotechnology company earns $-1,020,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

ImmuCell employs 52 workers across the globe.

The official website for ImmuCell is www.immucell.com.

ImmuCell is headquartered at 56 EVERGREEN DR, PORTLAND ME, 04103.

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]